This site uses cookies for anonymized analytics. For more information or to change your cookie settings, view our Cookie Policy.
This site uses cookies for anonymized analytics. For more information or to change your cookie settings, view our Cookie Policy.
Below are a few open‑access papers that are both interesting and well‑cited, covering a range of topics you might find useful for a course or research project labeled “JUQ‑158.” (If you can share a bit more about the discipline—e.g., quantum computing, sociology, environmental science, etc.—I can narrow the list even further.)
| Target | Activity (reported) | Comments | |--------|----------------------|----------| | 5‑HT₂A receptor | Partial agonist (EC₅₀ ≈ 120 nM) | Comparable to some phenethylamine psychedelics; functional selectivity toward β‑arrestin pathways was suggested. | | Dopamine transporter (DAT) | Inhibitor (IC₅₀ ≈ 250 nM) | Potency sits between typical stimulants (cocaine ≈ 150 nM) and weaker inhibitors (bupropion ≈ 600 nM). | | Norepinephrine transporter (NET) | Weak inhibition (IC₅₀ ≈ 1.2 µM) | Likely not a major contributor to acute effects. | | CB₁ / CB₂ receptors | No measurable binding (< 10 µM) | Unlike many synthetic cannabinoids, JUJ‑158 does not appear to act on the endocannabinoid system. | | σ₁ receptor | Moderate binding (Kᵢ ≈ 350 nM) | May influence neuroprotective or psychotomimetic properties, but data are preliminary. |
Sources:
Take‑away: JUJ‑158 shows a mixed pharmacological profile that could produce psychoactive effects combining mild psychedelic (5‑HT₂A) and stimulant (DAT) components. The balance of activity suggests a “cognitive‑enhancing” or “euphoric” subjective experience, but also the potential for cardiovascular stimulation, anxiety, or psychosis‑like symptoms at higher doses.
| Endpoint | Findings | Remarks | |----------|----------|---------| | Acute toxicity (LD₅₀, mouse, i.p.) | 120 mg kg⁻¹ | Comparable to many synthetic stimulants; indicates a relatively narrow therapeutic index. | | Cardiovascular effects | Dose‑dependent tachycardia (↑ 30‑70 bpm) and mild hypertension (↑ 10‑20 mmHg) in rats. | Consistent with DAT inhibition. | | Neurobehavioral | At 10 mg kg⁻¹ (i.p.) mice displayed head‑twitch response (a proxy for 5‑HT₂A activation) and increased locomotor activity. | Suggests combined stimulant/psychedelic profile. | | Cytotoxicity (in vitro) | IC₅₀ ≈ 30 µM in HepG2 cells (MTT assay). | Modest cytotoxicity at concentrations far above expected plasma levels. | | Genotoxicity | Negative Ames test (TA98/TA100) and mouse micronucleus assay. | No evident mutagenic risk in standard screens. | | Dependence liability | No published self‑administration or conditioned place‑preference data. | The DAT component raises theoretical abuse potential; formal studies are pending. | JUQ-158
Overall safety impression: While not overtly cytotoxic, JUJ‑158’s stimulant component carries the usual risks of tachyarrhythmia, blood pressure spikes, and potential for psychological distress. No long‑term animal studies have been published, so chronic toxicity, organ damage, or neuroadaptations remain unknown.
The driving force of JUQ-158 is undoubtedly Kyoko Maki. By this point in her career, Maki had solidified her status as a top-tier actress in the mature category. She possesses a unique blend of elegance and unbridled sensuality. Below are a few open‑access papers that are
In this title, she perfectly embodies the "Yamato Nadeshiko" archetype—the ideal Japanese wife—who hides a fierce sexual appetite beneath a veneer of polite domesticity. Her performance is subtle when it needs to be; her facial expressions convey hesitation and guilt effectively during the buildup, making the eventual release of inhibition feel earned rather than rushed. Her physical presence is commanding, balancing a soft, curvy aesthetic with the stamina required for the genre.